Extract
哮喘恶化对患者的生活质量产生了重大影响,并占哮喘直接医疗支出的80%[1,2]。许多哮喘患者受到针对炎症途径的治疗的帮助,并通过监测症状和恶化来评估功效。呼出一氧化氮的分数浓度(FENO) has been proposed as an objective measure of treatment efficacy in reducing eosinophilic, especially type 2 (T2)-high inflammation, a key mechanism underlying exacerbations [3]. Assessment ofFENOat a conventional expiratory flow rate of 50 mL·s−1(FENO50) has been standardised [4, 5] and is now recommended as providing complementary information for asthma diagnosis [6] and treatment [7].
Abstract
Alveolar inflammation, as assessed by partitioned exhaled nitric oxide, appears to provide promising insights into small airway disease relevant to asthma exacerbationhttps://bit.ly/38KqyCk
Footnotes
Conflict of interest: S.P. Eckel, E. Garcia and F.D. Gilliland all report NIH grants paid to their institution in the past 36 months, and no other conflicts of interest.
- Received2022年4月21日。
- Accepted2022年4月24日。
- 复制right ©The authors 2022. For reproduction rights and permissions contactpermissions{at}ersnet.org